Immunome (IMNM) Profit After Tax (2023 - 2025)
Historic Profit After Tax for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to -$57.5 million.
- Immunome's Profit After Tax fell 2198.94% to -$57.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$222.7 million, marking a year-over-year increase of 2705.27%. This contributed to the annual value of -$293.0 million for FY2024, which is 17429.45% down from last year.
- According to the latest figures from Q3 2025, Immunome's Profit After Tax is -$57.5 million, which was down 2198.94% from -$43.4 million recorded in Q2 2025.
- Immunome's 5-year Profit After Tax high stood at -$4.3 million for Q1 2023, and its period low was -$129.5 million during Q1 2024.
- Over the past 3 years, Immunome's median Profit After Tax value was -$43.4 million (recorded in 2025), while the average stood at -$49.3 million.
- Per our database at Business Quant, Immunome's Profit After Tax crashed by 293259.95% in 2024 and then surged by 6784.36% in 2025.
- Immunome's Profit After Tax (Quarter) stood at -$92.6 million in 2023, then grew by 13.37% to -$80.2 million in 2024, then increased by 28.4% to -$57.5 million in 2025.
- Its Profit After Tax was -$57.5 million in Q3 2025, compared to -$43.4 million in Q2 2025 and -$41.6 million in Q1 2025.